3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Lymphoma, Non-Hodgkin
5
Breast Neoplasms
5
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Hodgkin Disease
4
Hematologic Neoplasms
4
Waldenstrom Macroglobulinemia
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Sezary Syndrome
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parathyroid Neoplasms
2
Otorhinolaryngologic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Mixed Tumor, Mesodermal
2
Mesothelioma, Cystic
2
Interventions
Fluorouracil
11
Gemcitabine
8
pembrolizumab
7
Leucovorin
7
Irinotecan
7
Paclitaxel
6
Oxaliplatin
5
Carboplatin
5
130-nm albumin-bound paclitaxel
5
Nivolumab
4
Cisplatin
4
Albumin-Bound Paclitaxel
4
Taxes
3
Ramucirumab
3
Radiosurgery
3
Pemetrexed
3
Docetaxel
3
Capecitabine
3
Bevacizumab
3
vandetanib
2
spartalizumab
2
selinexor
2
osimertinib
2
folfirinox
2
Radiation
2
Cyclophosphamide
2
zolbetuximab
1
trastuzumab deruxtecan
1
trametinib
1
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Adenocarcinoma
×
belinostat
×
Clear all
NCT04315155
2020-10-28
BENEFIT
University of Utah
Phase 1
Withdrawn